Clinical Summary: Procognitive Effects of Antidepressants and Other Therapeutic Agents in Major Depressive Disorder: A Systematic Review
Many patients with major depressive disorder continue to struggle with attention, memory, processing speed, and executive dysfunction even after mood symptoms improve, and these deficits are closely tied to work and social impairment. This review matters because medication choices for major depressive disorder are usually guided by mood response, yet clinicians increasingly need evidence on which agents also improve objective cognitive performance.
Key Findings
- In the largest vortioxetine trial, 8 weeks of treatment in participants with moderate depression (N = 598; mean MADRS = 31.5) showed that 10 mg/d and 20 mg/d were significantly superior to placebo in improving global cognition, with the largest effect sizes on the DSST (d = 0.51 for 10 mg and d = 0.52 for 20 mg).
- Functional results for vortioxetine were mixed, but one 8-week study found significant improvement in functional capacity (N = 508, P < .001), and cognitive change correlated with functional change in 2 studies (r = 0.21, P = .02; r = 0.31, P = .006).
- Levomilnacipran improved attention and reaction time versus placebo after 8 weeks in severely depressed individuals (N = 429; mean MADRS = 35.2), with greater improvements among those who were more cognitively impaired at baseline.
- Desvenlafaxine was associated with significant improvement in global cognition after 8 weeks of open-label treatment (N = 36; d = 0.43, P = .003) and also improved functional measures on the Lam Employment Absence and Productivity Scale (d = 1.35, P < .001), Sheehan Disability Scale (d = 1.45, P < .001), and Health and Work Performance Questionnaire (d = 0.89, P < .001).
- Among non-antidepressant agents, erythropoietin enhanced recall memory and recognition memory more than placebo over 8 weeks in treatment-resistant depression, with effects maintained over the entire 14 weeks of the study (N = 39), whereas intranasal insulin showed no cognitive effects after 12 weeks (N = 35).
For cognitive impairment in major depressive disorder, vortioxetine has the strongest and most consistent support on objective cognitive measures, particularly for executive functioning, processing speed, and attention. Bupropion, some SNRIs, and selected augmentation agents show promising signals, but much of that evidence comes from smaller or uncontrolled studies.
Practice Implications
- When cognitive symptoms are a treatment priority in major depressive disorder, consider vortioxetine first because it showed placebo-controlled benefits on global cognition and DSST performance after 8 weeks.
- Do not assume mood response equals cognitive recovery; monitor objective cognition and day-to-day functioning separately, since several studies found cognitive gains were partly independent of depressive symptom improvement and functional results were inconsistent.
- If baseline cognitive impairment is prominent, especially slowed attention or reaction time, levomilnacipran may be worth considering because greater benefit was reported in patients who were more cognitively impaired at baseline.
- Use caution when translating positive findings from modafinil, caffeine, l-theanine, and open-label antidepressant studies into routine practice, because many trials had small samples, short durations, or no placebo control.
